Cynata completes $1.5m share placement to fund Cymerus cell therapy pipeline

An announcement from Cynata Therapeutics Limited ( (AU:CYP) ) is now available.

Cynata Therapeutics has completed a share placement, issuing 6,000,000 fully paid ordinary shares at $0.25 each, raising additional equity capital without the need for a prospectus under Australian corporations law. The company confirmed it is compliant with relevant financial reporting and continuous disclosure obligations and stated there is no excluded information that would be required to be disclosed to investors.

The placement strengthens Cynata’s balance sheet as it advances its Cymerus-based cell therapy pipeline through multiple late-stage clinical trials, including Phase 2 and Phase 3 studies in graft versus host disease, kidney transplantation and osteoarthritis. This capital injection supports ongoing development and potentially enhances the company’s positioning in the regenerative medicine sector as it seeks to progress its candidates toward commercialisation.

More about Cynata Therapeutics Limited

Cynata Therapeutics Limited is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus platform. The technology uses induced pluripotent stem cells to enable economical, scalable manufacture of mesenchymal stem cell products without relying on multiple tissue donors. Cynata’s pipeline includes Cymerus-derived candidates in clinical trials for graft versus host disease, diabetic foot ulcers, kidney transplantation and osteoarthritis, alongside preclinical programs in several cardiovascular and inflammatory conditions.

Average Trading Volume: 209,219

Technical Sentiment Signal: Buy

Current Market Cap: A$73.61M

Find detailed analytics on CYP stock on TipRanks’ Stock Analysis page.